Winrevair (Sotatercept-csrk) for Pulmonary Hypertension

Overview
Winrevair is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization group 1). It is used to help increase exercise capacity, improve WHO functional class, and reduce the risk of disease progression. Winrevair is also known by its drug name, sotatercept-csrk.

Winrevair functions as an activin signaling inhibitor. This category of drug works by interfering with certain cellular signals that contribute to worsening PAH, helping to alleviate symptoms and potentially slow disease progression.

How do I take it?
Winrevair is administered via subcutaneous (under the skin) injection. After initial treatment, most people need one injection every three weeks. Your doctor may adjust your dose based on changes in your blood hemoglobin and platelet counts. You should have these blood levels checked before each dose for the first five doses and periodically thereafter. Winrevair should be taken exactly as prescribed by a health care provider.

Side effects
Common side effects of Winrevair include headaches, nosebleeds, rash, small dilated blood vessels near the skin’s surface, diarrhea, dizziness, and skin redness and discoloration.

Rare but serious side effects may include severe thrombocytopenia (low platelet count), which can increase the risk of bleeding, and erythrocytosis (high red blood cell count), which may lead to blood clots and hyperviscosity syndrome (thickened blood). You should be monitored for these conditions as part of your regular medical checkups. Winrevair may cause fetal harm for pregnant people, so you should use contraception if there is a possibility of becoming pregnant.

For more information about this treatment, visit:

Winrevair — Merck

Winrevair — Drugs.com